Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:

Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

Abstract: The present invention provides a pyrimidine nucleoside compound represented by the following formula (1): [wherein one of X and Y is cyano and the other is hydrogen; and i) R1 is hydrogen, and R2 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C5-12 alkyl (the alkyl may be substituted), or alternatively, ii) R1 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C9 alkyl or alkenyloxycarbonyl wherein the alkenyl moiety is straight or branched C9 alkenyl, and R2 is hydrogen] or a salt thereof. The pyrimidine nucleoside compound or a salt thereof of the present invention shows a higher antitumor effect than existing pyrimidine nucleoside compounds.

Abstract: The present invention provides a pyrimidine nucleoside compound represented by the following formula (1): [wherein one of X and Y is cyano and the other is hydrogen; and i) R1 is hydrogen, and R2 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C5-12 alkyl (the alkyl may be substituted), or alternatively, ii) R1 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C9 alkyl or alkenyloxycarbonyl wherein the alkenyl moiety is straight or branched C9 alkenyl, and R2 is hydrogen] or a salt thereof. The pyrimidine nucleoside compound or a salt thereof of the present invention shows a higher antitumor effect than existing pyrimidine nucleoside compounds.